The potential of clofarabine in MLL -rearranged infant acute lymphoblastic leukaemia
- 1 September 2015
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (14) , 2008-2021
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic SyndromesSeminars in Oncology, 2011
- Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemiaBritish Journal of Haematology, 2011
- Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targetingBlood, 2010
- Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic optionsBlood, 2009
- DNA methylation analysis by pyrosequencingNature Protocols, 2007
- Discovery and development of clofarabine: a nucleoside analogue for treating cancerNature Reviews Drug Discovery, 2006
- Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2006
- Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemiaLeukemia, 2005
- DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer TherapiesJNCI: Journal of the National Cancer Institute, 2005
- In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeLeukemia, 2004